Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPD | P32754 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019621 | 0.93 | MAOB (0.51) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL14327913 | 0.85 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL14329204 | 0.82 | MEN1 (0.46) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL14327910 | 0.82 | MEN1 (0.51) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL14327889 | 0.82 | MEN1 (0.51) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL14327908 | 0.82 | MEN1 (0.51) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL9736347 | 0.82 | GALR3 (0.41) | MEN1KMT2AMAOBMAOAHRH3 | |
| SCHEMBL9844694 | 0.82 | HRH3 (0.47) | MEN1KMT2AHRH3ALDH1A1HPGD | |
| SCHEMBL16918467 | 0.82 | SRD5A2 (0.50) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL2016771 | 0.82 | SRD5A2 (0.50) | NPC1RAB9AMEN1KMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105816453-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-2342205-B1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2542554-B1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARM INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2542554-B1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARM INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-9108969-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9085581-B2 | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-5428043-A | Tricyclic-cyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1992021678-A1 | LIPOXYGENASE INHIBITING PYRROLO [1,2a]INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | NPC1 893/4885RAB9A 3522/4885MEN1 477/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | NPC1 893/4885RAB9A 3522/4885MEN1 477/4885 |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | NPC1 750/4885RAB9A 2135/4885MEN1 2072/4885 |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | NPC1 781/4885RAB9A 2139/4885MEN1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.